Cargando…

Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma

BACKGROUND: First-line treatment for metastatic renal cell carcinoma (mRCC) is rapidly changing. It currently includes VEGF targeted therapies (TT), multi-target tyrosine kinase inhibitors (TKIs), mTOR inhibitors, and immunotherapy. To optimize outcomes for individual patients, genomic markers of re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stenehjem, David D., Hahn, Andrew W., Gill, David M., Albertson, Daniel, Gowrishankar, Banumathy, Merriman, Joseph, Agarwal, Archana M., Thodima, Venkata, Harrington, Erik B., Au, Trang H., Maughan, Benjamin L., Houldsworth, Jane, Pal, Sumanta K., Agarwal, Neeraj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347137/ https://www.ncbi.nlm.nih.gov/pubmed/30682039 http://dx.doi.org/10.1371/journal.pone.0210415

Ejemplares similares

Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma
por: Kuzman, James A., et al.
Publicado: (2017)

Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications
por: Hahn, Andrew W., et al.
Publicado: (2017)

Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2
por: Gill, David M, et al.
Publicado: (2016)

Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome
por: Hahn, Andrew W., et al.
Publicado: (2018)

Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma
por: Tantravahi, Srinivas K., et al.
Publicado: (2015)

The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma
por: Rathi, Nityam, et al.
Publicado: (2019)

Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers
por: Maughan, Benjamin L., et al.
Publicado: (2017)

Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States
por: Swami, Umang, et al.
Publicado: (2021)

Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer
por: Patel, Jesal C., et al.
Publicado: (2013)

Subtyping of renal cortical neoplasms in fine needle aspiration biopsies using a decision tree based on genomic alterations detected by fluorescence in situ hybridization
por: Gowrishankar, Banumathy, et al.
Publicado: (2014)

Impact of Time to Metastasis (Synchronous vs. Metachronous) on Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with First Line Immune-Checkpoint Inhibitors (ICI)-based Combinations
por: Meza, Luis, et al.
Publicado: (2023)

RiboaptDB: A Comprehensive Database of Ribozymes and Aptamers
por: Thodima, Venkata, et al.
Publicado: (2006)

Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High‐Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial
por: Maughan, Benjamin L., et al.
Publicado: (2018)

Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
por: Rathi, Nityam, et al.
Publicado: (2020)

Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities
por: Sirohi, Deepika, et al.
Publicado: (2018)

Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
por: Gebrael, Georges, et al.
Publicado: (2023)

Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies
por: Guha, Avirup, et al.
Publicado: (2022)

DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC)
por: Rathi, Nityam, et al.
Publicado: (2018)

Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions
por: Gupta, Shilpa, et al.
Publicado: (2017)

Genome-Wide Promoter Methylome of Small Renal Masses
por: Ibragimova, Ilsiya, et al.
Publicado: (2013)

The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas
por: Hahn, Andrew W., et al.
Publicado: (2020)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma
por: Li, Haoran, et al.
Publicado: (2023)

Enhancing Triage Efficiency and Accuracy in Emergency Rooms for Patients with Metastatic Prostate Cancer: A Retrospective Analysis of Artificial Intelligence-Assisted Triage Using ChatGPT 4.0
por: Gebrael, Georges, et al.
Publicado: (2023)

Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors
por: Pal, Sumanta Kumar, et al.
Publicado: (2010)

Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation
por: Kmak, Jamie A., et al.
Publicado: (2020)

Clinical assessment of dietary interventions and lifestyle modifications in Madhumeha (type- 2 Diabetes Mellitus)
por: Gupta, Archana, et al.
Publicado: (2014)

The Management of Metastatic Castrate-Sensitive Prostate Cancer: From Guidelines to Real-World Practice
por: Gebrael, Georges, et al.
Publicado: (2023)

Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors
por: Chung, Jon H., et al.
Publicado: (2019)

Next Generation Sequencing in metastatic castrate-resistant prostate cancer
por: Adashek, Jacob J., et al.
Publicado: (2018)

Analysis and functional annotation of expressed sequence tags from the fall armyworm Spodoptera frugiperda
por: Deng, Youping, et al.
Publicado: (2006)

Therapeutic Sequencing in Metastatic Renal Cell Carcinoma
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer
por: Rathi, Nityam, et al.
Publicado: (2020)

Asiatic Acid Inhibits Pro-Angiogenic Effects of VEGF and Human Gliomas in Endothelial Cell Culture Models
por: Kavitha, Chandagirikoppal V., et al.
Publicado: (2011)

Impact of a genetic counseling requirement prior to genetic testing
por: Stenehjem, David D., et al.
Publicado: (2018)

The Gut Microbiome and Metastatic Renal Cell Carcinoma
por: Meza, Luis, et al.
Publicado: (2023)

The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer
por: Lieu, Christopher H., et al.
Publicado: (2013)

Live bacterial supplementation for improving treatment response in metastatic renal cell carcinoma
por: Meza, Luis, et al.
Publicado: (2022)

Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
por: Cheng, Heather H., et al.
Publicado: (2015)

Grave's disease with transverse and sigmoid sinus thrombosis needing surgical intervention
por: Srikant, Banumathy, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fd7j9v7cvd0dt5di950b3tqlmb